美國疾控中心:Moderna與mRNA新冠疫苗或與心肌炎有關
美國疾病控制與預防中心(CDC)表示,輝瑞(PFE.US)及Moderna(MRNA.US)的信使核糖核酸(mRNA)新冠疫苗可能與年輕人出現心肌炎有關,將迅速採取行動在疫情的說明書中添加相關的警告。
在接種第二劑疫苗後的男性在一週內出現心肌炎的病例似乎明顯增加,目前CDC已確定309宗因心肌炎入院的30歲以下人士,當中295人已出院。
CDC表示,接種疫苗後出現心肌炎的患者通常很快就會感覺好轉,認爲相關的疫苗好處明顯大於風險,強調疫苗安全有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.